Date: 2017-07-13
Type of information: Nomination
Compound:
Company: Achaogen (USA - CA)
Therapeutic area: Infectious diseases
Type agreement: nomination
Action mechanism:
Disease:
Details:
- • On July 13, 2017, Achaogen announced the appointment of Dr. Karen Bernstein, co-Founder and chairman of BioCentury Inc., to its Board of Directors. Dr. Bernstein brings to Achaogen significant leadership and three decades of experience writing and publishing on biotechnology developments. In addition, the Company announced that effective July 31, 2017, Alan Colowick, M.D., M.P.H., will step down as a Board member of the Company to focus on his new role as a Partner at Sofinnova Ventures.
- Dr. Bernstein is currently the Chairman of BioCentury Inc. which she co-founded, and for which she was Chairman and Editor-in-Chief from 1992 to 2015. She has received numerous awards for her contributions to the biotechnology industry including being named one of The WorldVIEW 100 most influential people in biotech today by Scientific American (2015) and receiving a Special Recognition award at the American Liver Foundation's Salute to Excellence, honoring individuals who have made an outstanding contribution to biotechnology and medical innovation (2007).
- She holds a Ph.D. in political science from Stanford University and a B.A. in politics and history from Brandeis University, where she served for many years as a member of the Brandeis University Science Advisory Council. She is on the board of trustees of the Keck Graduate Institute (KGI) of the Applied Life Sciences and is a member of the board of advisors of KGI's School of Pharmacy. She is a director at Ovid Therapeutics Inc., which is focused on developing drugs for orphan diseases of the brain. From September 2015 to October 2016, she also served on the board of directors of Vitae Pharmaceuticals, which was acquired by Allergan.
Financial terms:
Latest news:
Is general: Yes
